Skip to content

Spyre Therapeutics, Inc. SYRE Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Webster Financial Corporation logo
Webster Financial CorporationWBS
$1.52M-53.8%
Viasat logo
ViasatVSAT
-$4.06M+95.9%
Sterling Infrastructure, Inc. logo
Sterling Infrastructure, Inc.STRL
$739K-5.5%
Cullen/Frost Bankers logo
Cullen/Frost BankersCFR
$191K-91.9%
Globe Life logo
Globe LifeGL
-$6.95M-14.9%
Life Time Group Holdings logo
Life Time Group HoldingsLTH
-$827K-546%

Other financials

Income statement

See full
Revenue-
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$7.67B+307%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s gain/loss on asset sales?
Spyre Therapeutics, Inc. (SYRE) reported gain/loss on asset sales of $30M in Q1 2026.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.